AstraZeneca PLCAZNNASDAQ
Loading
Book Value/Share Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR+8.9%
5Y CAGR-14.2%
Year-over-Year Change
Year-over-year book value per share growth
3Y CAGR
+8.9%/yr
Quarterly compound
5Y CAGR
-14.2%/yr
Recent acceleration
Percentile
P79
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.91% |
| Q3 2025 | 1.70% |
| Q2 2025 | 8.94% |
| Q1 2025 | 0.64% |
| Q4 2024 | 0.42% |
| Q3 2024 | 3.05% |
| Q2 2024 | 5.25% |
| Q1 2024 | -4.25% |
| Q4 2023 | 5.23% |
| Q3 2023 | -0.46% |
| Q2 2023 | 4.41% |
| Q1 2023 | -3.36% |
| Q4 2022 | 5.35% |
| Q3 2022 | -2.15% |
| Q2 2022 | -1.19% |
| Q1 2022 | -7.51% |
| Q4 2021 | -4.81% |
| Q3 2021 | 123.05% |
| Q2 2021 | 8.63% |
| Q1 2021 | -7.62% |
| Q4 2020 | 14.83% |
| Q3 2020 | -0.29% |
| Q2 2020 | 11.80% |
| Q1 2020 | -16.31% |
| Q4 2019 | 6.78% |
| Q3 2019 | -9.37% |
| Q2 2019 | 21.08% |
| Q1 2019 | -14.35% |
| Q4 2018 | 3.75% |
| Q3 2018 | -5.15% |
| Q2 2018 | -2.14% |
| Q1 2018 | -12.43% |
| Q4 2017 | 7.74% |
| Q3 2017 | 0.23% |
| Q2 2017 | 4.20% |
| Q1 2017 | -11.34% |
| Q4 2016 | 11.78% |
| Q3 2016 | -3.11% |
| Q2 2016 | -7.60% |
| Q1 2016 | -10.09% |